|
1
|
Chou AJ, Geller DS and Gorlick R: Therapy
for osteosarcoma: where do we go from here? Paediatr Drugs.
10:315–327. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dai X, Ma W, He X and Jha RK: Review of
therapeutic strategies for osteosarcoma, chondrosarcoma, and
Ewing’s sarcoma. Med Sci Monit. 17:177–190. 2011.
|
|
3
|
Kim SY and Helman LJ: Strategies to
explore new approaches in the investigation and treatment of
osteosarcoma. Cancer Treat Res. 152:517–528. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hattinger CM, Pasello M, Ferrari S, Picci
P and Serra M: Emerging drugs for high-grade osteosarcoma. Expert
Opin Emerg Drugs. 15:615–634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gutierrez ME, Kummar S and Giaccone G:
Next generation oncology drug development: opportunities and
challenges. Nat Rev Clin Oncol. 6:259–265. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Raina K and Agarwal R: Combinatorial
strategies for cancer eradication by silibinin and cytotoxic
agents: efficacy and mechanisms. Acta Pharmacol Sin. 28:1466–1475.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Szekeres T, Saiko P, Fritzer-Szekeres M,
Djavan B and Jäger W: Chemopreventive effects of resveratrol and
resveratrol derivatives. Ann NY Acad Sci. 1215:89–95. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tian L, Yin D, Ren Y, Gong C, Chen A and
Guo FJ: Plumbagin induces apoptosis via the p53 pathway and
generation of reactive oxygen species in human osteosarcoma cells.
Mol Med Rep. 5:126–132. 2012.PubMed/NCBI
|
|
9
|
Wu CL, Huang AC, Yang JS, et al: Benzyl
isothiocyanate (BITC) and phenethyl isothiocyanate (PEITC)-mediated
generation of reactive oxygen species causes cell cycle arrest and
induces apoptosis via activation of caspase-3, mitochondria
dysfunction and nitric oxide (NO) in human osteogenic sarcoma U-2
OS cells. J Orthop Res. 29:1199–1209. 2011.
|
|
10
|
Maran A, Shogren KL, Benedikt M, Sarkar G,
Turner RT and Yaszemski MJ: 2-Methoxyestradiol-induced cell death
in osteosarcoma cells is preceded by cell cycle arrest. J Cell
Biochem. 104:1937–1945. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen JT, Fong YC, Li TM, et al: DDTD, an
isoflavone derivative, induces cell apoptosis through the reactive
oxygen species/apoptosis signal-regulating kinase 1 pathway in
human osteosarcoma cells. Eur J Pharmacol. 597:19–26. 2008.
View Article : Google Scholar
|
|
12
|
Yoshiko Y, Candeliere GA, Maeda N and
Aubin JE: Osteoblast autonomous Pi regulation via Pit1 plays a role
in bone mineralization. Mol Cell Biol. 27:4465–4474. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takeda E, Taketani Y, Sawada N, Sato T and
Yamamoto H: The regulation and function of phosphate in the human
body. Biofactors. 21:345–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Prié D, Beck L, Urena P and Friedlander G:
Recent findings in phosphate homeostasis. Curr Opin Nephrol
Hypertens. 14:318–324. 2005.
|
|
15
|
Khoshniat S, Bourgine A, Julien M, Weiss
P, Guicheux J and Beck L: The emergence of phosphate as a specific
signaling molecule in bone and other cell types in mammals. Cell
Mol Life Sci. 68:205–218. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Naviglio S, Spina A, Chiosi E, et al:
Inorganic phosphate inhibits growth of human osteosarcoma U2OS
cells via adenylate cyclase/cAMP pathway. J Cell Biochem.
98:1584–1596. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Naviglio S, Di Gesto D, Borrelli V, et al:
Novel molecular mechanisms by inorganic phosphate in osteosarcoma
U2OS cells. Front Biosci. 3:1249–1258. 2011.PubMed/NCBI
|
|
18
|
Spina A, Sorvillo L, Di Maiolo F, et al:
Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS
cells to doxorubicin via a p53-dependent pathway. J Cell Physiol.
228:198–206. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Camalier CE, Young MR, Bobe G, Perella CM,
Colburn NH and Beck GR Jr: Elevated phosphate activates N-ras and
promotes cell transformation and skin tumorigenesis. Cancer Prev
Res. 3:359–370. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zou J, Gan M, Mao N, Zhu X, Shi Q and Yang
H: Sensitization of osteosarcoma cell line SaOS-2 to chemotherapy
by downregulating survivin. Arch Med Res. 41:162–169. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Olijslagers SJ, Zhang YH, Backendorf C and
Noteborn MH: Additive cytotoxic effect of apoptin and
chemotherapeutic agents paclitaxel and etoposide on human tumour
cells. Basic Clin Pharmacol Toxicol. 100:127–131. 2007.PubMed/NCBI
|
|
22
|
Mao FJ, Sidorova JM, Lauper JM, Emond MJ
and Monnat RJ: The human WRN and BLM RecQ helicases differentially
regulate cell proliferation and survival after chemotherapeutic DNA
damage. Cancer Res. 70:6548–6555. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Naviglio S, Di Gesto D, Romano M, et al:
Leptin enhances growth inhibition by cAMP elevating agents through
apoptosis of MDA-MB-231 breast cancer cells. Cancer Biol Ther.
8:1183–1190. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Naviglio S, Di Gesto D, Illiano F, et al:
Leptin potentiates antiproliferative action of cAMP elevation via
protein kinase A down-regulation in breast cancer cells. J Cell
Physiol. 225:801–809. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Naviglio S, Mattecucci C, Matoskova B, et
al: UBPY: a growth-regulated human ubiquitin isopeptidase. EMBO J.
17:3241–3250. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lamberti M, Porto S, Marra M, et al:
5-Fluorouracil induces apoptosis in rat cardiocytes through
intracellular oxidative stress. J Exp Clin Cancer Res. 31:60–68.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bradford MM: A rapid and sensitive method
for the quantification of microgram quantities of protein utilizing
the principle of protein dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu KH, Lue KH, Chou MC and Chung JG:
Paclitaxel induces apoptosis via caspase-3 activation in human
osteogenic sarcoma cells (U-2 OS). J Orthop Res. 23:988–994. 2005.
View Article : Google Scholar
|
|
29
|
Zhu JJ, Li FB, Zhou JM, Liu ZC, Zhu XF and
Liao WM: The tumor suppressor p33ING1b enhances taxol-induced
apoptosis by p53-dependent pathway in human osteosarcoma U2OS
cells. Cancer Biol Ther. 4:39–47. 2005.PubMed/NCBI
|
|
30
|
Song B, Wang Y, Xi Y, et al: Mechanism of
chemoresistance mediated by miR-140 in human osteosarcoma and colon
cancer cells. Oncogene. 28:4065–4074. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Im YS, Shin HK, Kim HR, et al: Enhanced
cytotoxicity of 5-FU by bFGF through up-regulation of uridine
phosphorylase 1. Mol Cells. 28:119–124. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Koto K, Murata H, Kimura S, et al:
Zoledronic acid inhibits proliferation of human fibrosarcoma cells
with induction of apoptosis, and shows combined effects with other
anticancer agents. Oncol Rep. 24:233–239. 2010.PubMed/NCBI
|
|
33
|
Varmeh S and Manfredi JJ: Overexpression
of the dual specificity phosphatase, Cdc25C, confers sensitivity on
tumor cells to doxorubicin-induced cell death. Mol Cancer Ther.
7:3789–3799. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zucchini C, Bianchini M, Valvassori L, et
al: Identification of candidate genes involved in the reversal of
malignant phenotype of osteosarcoma cells transfected with the
liver/bone/kidney alkaline phosphatase gene. Bone. 34:672–679.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Agner J, Falck J, Lukas J and Bartek J:
Differential impact of diverse anticancer chemotherapeutics on the
Cdc25A-degradation checkpoint pathway. Exp Cell Res. 302:162–169.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gewirtz DA: A critical evaluation of the
mechanisms of action proposed for the antitumor effects of the
anthracycline antibiotics adriamycin and daunorubicin. Biochem
Pharmacol. 57:727–741. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tentner AR, Lee MJ, Ostheimer GJ, Samson
LD, Lauffenburger DA and Yaffe MB: Combined experimental and
computational analysis of DNA damage signaling reveals
context-dependent roles for Erk in apoptosis and G1/S arrest after
genotoxic stress. Mol Syst Biol. 31:1–18. 2012.
|
|
38
|
Yuan XW, Zhu XF, Huang XF, et al:
Interferon-alpha enhances sensitivity of human osteosarcoma U2OS
cells to doxorubicin by p53-dependent apoptosis. Acta Pharmacol
Sin. 28:1835–1841. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chiosi E, Spina A, Sorrentino A, et al:
Change in TNF-alpha receptor expression is a relevant event in
doxorubicin-induced H9c2 cardiomyocyte cell death. J Interferon
Cytokine Res. 27:589–597. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhao P and Astruc D: Docetaxel
nanotechnology in anticancer therapy. Chem Med Chem. 7:952–972.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lopez-Heredia MA, Kamphuis GJ, Thüne PC,
Öner FC, Jansen JA and Walboomers XF: An injectable calcium
phosphate cement for the local delivery of paclitaxel to bone.
Biomaterials. 32:5411–5416. 2011. View Article : Google Scholar : PubMed/NCBI
|
